Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease.
10.3350/cmh.2012.18.4.383
- Author:
Min Sun KWAK
1
;
Donghee KIM
;
Goh Eun CHUNG
;
Seung Joo KANG
;
Min Jung PARK
;
Yoon Jun KIM
;
Jung Hwan YOON
;
Hyo Suk LEE
Author Information
1. Department of Internal Medicine, Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea. messmd@chol.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Nonalcoholic fatty liver disease (NAFLD);
Bilirubin
- MeSH:
Adult;
Alcohol Drinking;
Bilirubin/*blood;
Cross-Sectional Studies;
DNA, Viral/blood;
Fatty Liver/complications/epidemiology/*ultrasonography;
Female;
Hepatitis B/complications;
Hepatitis C/complications;
Humans;
Male;
Middle Aged;
Odds Ratio;
Prevalence;
RNA, Viral/blood;
Regression Analysis;
Risk Factors;
Young Adult
- From:Clinical and Molecular Hepatology
2012;18(4):383-390
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Serum bilirubin exerts antioxidant and cytoprotective effects. In addition, elevated serum bilirubin levels are associated with a decreased risk of metabolic and cardiovascular diseases. However, few studies have evaluated whether serum bilirubin is associated with non-alcoholic fatty liver disease (NAFLD), which is closely associated with other metabolic diseases. The aim of this study was thus to elucidate the association between serum total bilirubin levels and NAFLD. METHODS: A cross-sectional study of 17,348 subjects undergoing a routine health check-up was conducted. Subjects positive for hepatitis B or hepatitis C virus, or with other hepatitis history were excluded. NAFLD was diagnosed on the basis of typical ultrasonographic findings and an alcohol consumption of less than 20 g/day. RESULTS: The mean age of the subjects was 49 years and 9,076 (52.3%) were men. The prevalence of NAFLD decreased steadily as the serum bilirubin level increased in both men and women (P<0.001 for both). Multivariate regression analysis adjusted for other metabolic risk factors showed that serum bilirubin level was inversely associated with the prevalence of NAFLD [odds ratio (OR)=0.88, 95% confidence interval (CI)=0.80-0.97]. Furthermore, there was an inverse, dose-dependent association between NAFLD and serum total bilirubin levels (OR=0.83, 95% CI=0.75-0.93 in the third quartile; OR=0.80, 95% CI=0.71-0.90 in the fourth quartile vs. lowest quartile, P for trend <0.001). CONCLUSIONS: Serum bilirubin levels were found to be inversely associated with the prevalence of NAFLD independent of known metabolic risk factors. Serum bilirubin might be a protective marker for NAFLD.
